EpCAM antibody (Extracellular)

Catalog No. ABIN4949641

The Mouse Monoclonal anti-EpCAM antibody is suitable to detect EpCAM in samples from Human, Cat, Dog and Guinea Pig. It has been validated for WB, IF, ELISA and IHC (p).

Quick Overview for EpCAM antibody (Extracellular) (ABIN4949641)

Target: EpCAM (EPCAM) (Epithelial Cell Adhesion Molecule (EPCAM))

Reactivity: Human, Cat, Dog, Guinea Pig

Host: Mouse

Clonality: Monoclonal

Conjugate: This EpCAM antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: EGP40-1384

Product Details anti-EpCAM Antibody

Binding Specificity: AA 100-224, Extracellular

Purpose: EpCAM Antibody / Extracellular domain (azide and preservative free)

Purification: Protein G affinity chromatography

Immunogen: A human partial recombinant protein corresponding to amino acids 100-224 (extracellular domain) was used as the immunogen for the EpCAM antibody.

Isotype: IgG

Application Details

Application Notes: Titering of the EpCAM antibody may be required for optimal performance.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the EpCAM antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Target Details for EpCAM

Target: EpCAM (EPCAM) (Epithelial Cell Adhesion Molecule (EPCAM))

Alternative Name: EpCAM

Background: EpCAM (Epithelial Cell Adhesion Molecule), also known as CD326, plays a crucial role in various cellular processes and has been linked to the development and progression of cancer. EpCAM is a transmembrane glycoprotein that is expressed in high levels on the surface of epithelial cells. In cancer cells, the expression of EpCAM is often upregulated, leading to increased cell proliferation, invasion, and metastasis. Studies have shown that high levels of EpCAM are associated with poor prognosis in various types of cancer, including breast, colon, and lung cancer. The overexpression of EpCAM in cancer cells makes it an attractive target for diagnostic and therapeutic purposes. Researchers are exploring the use of EpCAM as a biomarker for early cancer detection through blood tests and imaging techniques. In addition, EpCAM-targeted therapies, such as monoclonal antibodies and immunotherapies, are being developed to specifically target and kill cancer cells that overexpress EpCAM.

UniProt: P16422